Apex Healthcare Berhad announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported revenue MYR 165,253,000 against MYR 157,730,000 a year ago. Profit before tax was MYR 18,637,000 against MYR 13,302,000 a year ago. Net profit attributable to owners of the parent was MYR 14,897,000 against MYR 11,270,000 a year ago. Diluted earnings per share attributable to owners of the parent were 12.64 sen against 9.61 sen a year ago. In the third quarter of 2018, the group achieved revenue a growth of 4.8% when compared to the third quarter of 2017. Revenue growth was also helped by higher contract manufacturing and public sector pharmaceutical sales in both Malaysia and Singapore. Share of profit from associate company Straits Apex Sdn Bhd was MYR 2.26 million, significantly improved over the MYR 0.72 million recognized in the third quarter of 2017. With a greater proportion of higher margin proprietary products in the sales mix, group profit before tax for the third quarter rose to MYR 18.6 million, 39.8% higher than the MYR 13.3 million achieved in the corresponding period in 2017. Profit before tax for the current quarter growth of 7.3% higher than compared to second quarter of 2018. This was due to higher revenue and improved margins arising from a better sales mix in the third quarter when compared to the immediate preceding quarter.

For the nine months, the company reported revenue MYR 489,599,000 against MYR 467,679,000 a year ago. Profit before tax was MYR 52,531,000 against MYR 39,667,000 a year ago. Net profit attributable to owners of the parent was MYR 41,777,000 against MYR 31,658,000 a year ago. Diluted earnings per share attributable to owners of the parent were 35.45 sen against 27.00 sen a year ago. Net assets per share attributable to owners of the parent were MYR 3.12 as on September 30, 2018, compared with MYR 2.93 as on December 31, 2017. For the first nine months of 2018, the group achieved revenue a growth of 4.7% when compared to the same period in 2017. Across the business units, revenue growth was strongest for private sector pharmaceutical and consumer healthcare products, international exports, sales to government agencies and contract manufacturing services.

For the third quarter ended September 30, 2018, the company reported property, plant and equipment written off of MYR 2,000 compared to MYR 1,000 a year ago.